• Je něco špatně v tomto záznamu ?

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

D. Schierova, R. Roubalova, M. Kolar, Z. Stehlikova, F. Rob, Z. Jackova, S. Coufal, T. Thon, M. Mihula, M. Modrak, M. Kverka, L. Bajer, K. Kostovcikova, P. Drastich, J. Hercogova, M. Novakova, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z....

. 2021 ; 10 (11) : . [pub] 20211116

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003196

Grantová podpora
grant number NV18-09-00493. Ministry of Health of the Czech Republic

Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003196
003      
CZ-PrNML
005      
20240206093047.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells10113188 $2 doi
035    __
$a (PubMed)34831411
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Schierova, Dagmar $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
245    10
$a Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy / $c D. Schierova, R. Roubalova, M. Kolar, Z. Stehlikova, F. Rob, Z. Jackova, S. Coufal, T. Thon, M. Mihula, M. Modrak, M. Kverka, L. Bajer, K. Kostovcikova, P. Drastich, J. Hercogova, M. Novakova, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z. Jiraskova Zakostelska
520    9_
$a Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x krev $7 D000906
650    _2
$a biodiverzita $7 D044822
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a feces $x mikrobiologie $7 D005243
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a houby $x genetika $7 D005658
650    12
$a střevní mikroflóra $x genetika $7 D000069196
650    _2
$a lidé $7 D006801
650    _2
$a idiopatické střevní záněty $x krev $x farmakoterapie $x mikrobiologie $x chirurgie $7 D015212
650    _2
$a interleukin-17 $x metabolismus $7 D020381
650    _2
$a leukocyty mononukleární $x metabolismus $7 D007963
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metagenomika $7 D056186
650    _2
$a RNA ribozomální 16S $x genetika $7 D012336
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Roubalova, Radka $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Kolar, Martin $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic
700    1_
$a Stehlikova, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Rob, Filip $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
700    1_
$a Jackova, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Coufal, Stepan $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Thon, Tomas $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Mihula, Martin $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Modrák, Martin $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic $7 xx0313530
700    1_
$a Kverka, Miloslav $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Bajer, Lukas $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic $u Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic
700    1_
$a Kostovcikova, Klara $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Drastich, Pavel $u Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic
700    1_
$a Hercogova, Jana $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
700    1_
$a Novakova, Michaela $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
700    1_
$a Vasatko, Martin $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic
700    1_
$a Tlaskalova-Hogenova, Helena $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Jiraskova Zakostelska, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 10, č. 11 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34831411 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240206093044 $b ABA008
999    __
$a ok $b bmc $g 1750839 $s 1154345
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 11 $e 20211116 $i 2073-4409 $m Cells $n Cells $x MED00194911
GRA    __
$a grant number NV18-09-00493. $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace